Bluejay Diagnostics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 9, 2025, details a material definitive agreement and unregistered sales of equity securities by Bluejay Diagnostics, Inc. The Company, an emerging growth company incorporated in Delaware, announced the pricing of a private placement on October 9, 2025, which closed on October 10, 2025.
Key Financial Metrics and Transaction Details
- Proceeds: The Company received approximately $4.0 million in net proceeds after payment of an 8% cash fee and reimbursement of expenses to the placement agent.
- Securities Issued:
- 175,000 shares of common stock.
- Pre-Funded Warrants to purchase up to 2,075,000 shares of common stock (exercise price: $0.0001).
- Series F Warrants to purchase up to 4,500,000 shares of common stock (exercise price: $1.75; expiration: 5.5 years).
- Placement Agent Warrants to purchase up to 180,000 shares of common stock (exercise price: 125% of the combined price).
- Pricing: The combined price was $2.00 per share of common stock (or pre-funded warrant) and accompanying Series F Warrants to acquire two shares.
- Placement Agent: Rodman and Renshaw LLC served as the exclusive placement agent.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement. Key terms include:
- Registration Rights: The Company agreed to file a resale registration statement by October 24, 2025, covering the 175,000 shares of common stock and 6,755,000 shares underlying the warrants. Failure to meet filing deadlines may result in liquidated damages.
- Lock-Up Provisions: The Company is restricted from issuing new equity or convertible securities for 90 days after the registration statement becomes effective. Additionally, for one year post-effectiveness, the Company cannot engage in variable rate transactions or stock splits without majority investor consent.
- Beneficial Ownership Limitations: Warrant holders are subject to beneficial ownership limits of 4.99% or 9.99% (at election), with provisions to adjust these limits upon 61 days' notice.
Outlook, Risks, and Contingencies
The filing does not provide specific financial guidance or management commentary regarding future operational performance. However, the transaction introduces the following contingencies and risks:
- Dilution: The issuance of significant warrant coverage (over 6.7 million shares) creates potential dilution for existing shareholders upon exercise.
- Compliance Risk: The Company faces financial penalties if it fails to file the resale registration statement by the October 24, 2025 deadline or fails to keep it effective.
- Restrictions on Capital Raising: The 90-day and one-year lock-up periods may limit the Company's ability to raise additional capital or restructure its capitalization in the near term.
Investor Verification Checklist
- Verify the filing date and effectiveness status of the resale registration statement (due by October 24, 2025).
- Confirm the total number of shares outstanding post-closing to assess the dilution impact of the 6,755,000 warrant shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific definitions of "variable rate transactions" and liquidated damages.
- Monitor subsequent press releases or filings for any updates on the use of the $4.0 million in proceeds.